

Drugs Treatment / Multiple Sclerosis

Reference Number: RDF1509-23

Date of Response: 15/06/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

I have a Freedom of information query. How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs:

	Total
Aubagio (teriflunomide)	83
Avonex (interferon beta-1a)	42
Betaferon (interferon beta-1b)	*<5
Brabio (glatiramer acetate)	0
Copaxone (glatiramer acetate)	50
Extavia (beta interferon-1b)	0
Gilenya (fingolimod)	34
Lemtrada (alemtuzumab)	3
Kesimpta (ofatumumab)	0
Mavenclad (cladribine)	7
Mayzent (siponimod)	15
Ocrevus (ocrelizumab)	47
Plegridy (peginterferon beta-1a)	44
Ponvory (ponesimod)	7
Rebif (beta interferon-1a)	24
Tecfidera (dimethyl fumarate)	181
Tysabri (natalizumab)	0
Tysabri (natalizumab) pre-filled syringes ONLY	154
Vumerity (diroximel fumarate)	0
Zeposia (ozanimod)	0

*<5 - In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients/staff is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients/staff and should not be published.

Please provide the number of active patients treated for Multiple Sclerosis.

Multiple sclerosis (any type)	516
Relapsing remitting multiple sclerosis (RRMS)	304
Primary progressive multiple sclerosis (PPMS)	51
Secondary progressive multiple sclerosis (SPMS)	109

[*] Please note these figures are presenting the number of patients with an active MS, RRMS, PPMS or SPMS diagnosis in the patient problem list who have had at least one encounter within the Trust.